The organizations moving fastest are the ones that adapt without losing precision.
This month, our four specialists show you where that balance appears: AI-driven quality systems reaching industry maturity, medical device ecosystems evolving beyond static documentation, governance frameworks that turn documentation into competitive advantage, and pharmaceutical reforms reshaping multilingual regulatory requirements across Europe.
Each section offers insight into building systems that adapt while maintaining regulatory integrity.
The Intertranslations Team
Quality Estimation: The Next Wave
Quality Estimation has come a long way since its early experimental days. TAUS predicts that by 2027, every translation operator around the world will have implemented QE. Right now, nearly 50% of the market still runs MTPE without proper Quality Estimation or AutoPE. This creates huge inefficiencies across the industry and billions in unnecessary costs. QE is quickly emerging as the next major wave of AI transformation in translation. At the upcoming TAUS Massively Multilingual AI Conference in Rome, practitioners from both enterprise and language technology will share what QE really looks like in real production settings: confidence scores, risk signals, and outcomes from high-stakes translation projects. This is not theory. This is what responsible automation looks like in regulated industries where precision shapes compliance results.
Discover what Quality Estimation means for your workflows.
When Translation Workflows Must Evolve With Connected Devices
If your medical device clients are shifting to connected platforms, eIFUs, apps, and IoT interfaces, your translation workflows need to evolve along with them. Static PDF-based processes are no longer enough. Modern device ecosystems require modular, version-controlled content stored as strings or structured data instead of large documents. Translation must be built directly into code and CI/CD pipelines, while glossaries and translation memories are actively updated with device-specific terminology. Full traceability from every translated string back to the risk management file and device build is critical for compliance and patient safety. Over-the-air updates, QR-linked e-labelling, and dynamic language switching add even more complexity. Translation partners who treat multilingual content as a living, software-integrated layer rather than a one-time project will be best positioned to support the next generation of connected devices.
Learn how adaptive device ecosystems are changing translation workflows.
How Many “Same” Documents Are Currently Active in Your System?
In technical and regulated industries, documentation is the evidence that proves a process was followed, a product was validated, or a standard was met. Good document governance means having one clear authoritative version that is always traceable. Every critical document should have a single source of truth with a complete version history, defined ownership, and a controlled approval process. Teams should always refer to the official record, not to local copies. Each document needs a named owner who is responsible for keeping it current. When an auditor requests a document, the speed and confidence of your response already say a lot about the strength of your governance even before they review the content. Structured systems make retrieval fast, reliable, and fully traceable. When documentation is managed as a living part of governance instead of a static archive, it stops being just a compliance task and becomes a real competitive advantage.
Explore how document governance protects audit readiness.
The EU Pharmaceutical Package: What It Means for Multilingual Documentation
The EU has released the provisional texts of the new Pharmaceutical Package, with formal adoption expected in summer 2026. This reform will significantly change data protection periods, market exclusivity rules, approval pathways, supply chain obligations, and efforts to prevent medicine shortages across Europe. What many discussions miss is the major documentation impact this will create. Updated SmPCs, Patient Information Leaflets, labelling, pharmacovigilance reports, clinical overviews, and supply chain files will all need accurate translation and localization into 24+ EU languages while maintaining full regulatory consistency and cultural suitability. Any terminology inconsistencies or unclear patient-facing language can lead to approval delays, compliance questions, or extra review cycles. From our experience supporting pharmaceutical companies, reforms on this scale are exactly when expert-led localization proves its value in the process.
Discover how to prepare for the 2026 EU Pharma Package.
Ready to Adapt and Grow?
Book your Consultation